MRPL48是一种新的肝细胞癌的预后和预测生物标志物

Yu-Xiang Lin1, Jun-Yong Pan2, Wen-Du Feng2

  • 1Central Supply Service Department, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, 36200, People's Republic of China.

PubMed
概括

线粒体核糖体蛋白L48 (MRPL48) 在肝细胞癌 (HCC) 中过度表达,并预测患者的预后. 针对MRPL48可能为HCC治疗提供新的治疗策略.

相关概念视频